• Something wrong with this record ?

Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine

M. Stiborova, M. Rupertova, HH. Schmeiser, E. Frei

. 2006 ; 150 (1) : 13-23.

Language English Country Czech Republic

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Ellipticine is a potent antineoplastic agent exhibiting the multimodal mechanism of its action. This article reviews the mechanisms of predominant pharmacological and cytotoxic effects of ellipticine and shows the results of our laboratories indicating a novel mechanism of its action. The prevalent mechanisms of ellipticine antitumor, mutagenic and cytotoxic activities were suggested to be intercalation into DNA and inhibition of DNA topoisomerase II activity. We demonstrated a new mode of ellipticine action, formation of covalent DNA adducts mediated by its oxidation with cytochromes P450 (CYP) and peroxidases. The article reports the molecular mechanism of ellipticine oxidation by CYPs and identifies human and rat CYPs responsible for ellipticine metabolic activation and detoxication. It also presents a role of peroxidases (i.e. myeloperoxidase, cyclooxygenases, lactoperoxidase) in ellipticine oxidation leading to ellipticine-DNA adducts. The 9-hydroxy- and 7-hydroxyellipticine metabolites formed by CYPs and the major product of ellipticine oxidation by peroxidases, the dimer, in which the two ellipticine skeletons are connected via N(6) of the pyrrole ring of one ellipticine molecule and C9 in the second one, are the detoxication metabolites. On the contrary, 13-hydroxy- and 12-hydroxyellipticine, produced by ellipticine oxidation with CYPs, the latter one formed also spontaneously from another CYP- and peroxidase-mediated metabolite, ellipticine N(2)-oxide, are metabolites responsible for formation of two ellipticine-derived deoxyguanosine adducts in DNA. The results reviewed here allow us to propose species, two carbenium ions, ellipticine-13-ylium and ellipticine-12-ylium, as reactive species generating two major DNA adducts seen in vivo in rats treated with ellipticine. The study forms the basis to further predict the susceptibility of human cancers to ellipticine.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13003704
003      
CZ-PrNML
005      
20130315141541.0
007      
ta
008      
130128s2006 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2006.002 $2 doi
035    __
$a (PubMed)16936898
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Stiborová, Marie, $d 1950-2020 $7 jo2005259907 $u Department of Biochemistry, Faculty of Science, Charles University, Prague 2
245    10
$a Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine / $c M. Stiborova, M. Rupertova, HH. Schmeiser, E. Frei
520    9_
$a Ellipticine is a potent antineoplastic agent exhibiting the multimodal mechanism of its action. This article reviews the mechanisms of predominant pharmacological and cytotoxic effects of ellipticine and shows the results of our laboratories indicating a novel mechanism of its action. The prevalent mechanisms of ellipticine antitumor, mutagenic and cytotoxic activities were suggested to be intercalation into DNA and inhibition of DNA topoisomerase II activity. We demonstrated a new mode of ellipticine action, formation of covalent DNA adducts mediated by its oxidation with cytochromes P450 (CYP) and peroxidases. The article reports the molecular mechanism of ellipticine oxidation by CYPs and identifies human and rat CYPs responsible for ellipticine metabolic activation and detoxication. It also presents a role of peroxidases (i.e. myeloperoxidase, cyclooxygenases, lactoperoxidase) in ellipticine oxidation leading to ellipticine-DNA adducts. The 9-hydroxy- and 7-hydroxyellipticine metabolites formed by CYPs and the major product of ellipticine oxidation by peroxidases, the dimer, in which the two ellipticine skeletons are connected via N(6) of the pyrrole ring of one ellipticine molecule and C9 in the second one, are the detoxication metabolites. On the contrary, 13-hydroxy- and 12-hydroxyellipticine, produced by ellipticine oxidation with CYPs, the latter one formed also spontaneously from another CYP- and peroxidase-mediated metabolite, ellipticine N(2)-oxide, are metabolites responsible for formation of two ellipticine-derived deoxyguanosine adducts in DNA. The results reviewed here allow us to propose species, two carbenium ions, ellipticine-13-ylium and ellipticine-12-ylium, as reactive species generating two major DNA adducts seen in vivo in rats treated with ellipticine. The study forms the basis to further predict the susceptibility of human cancers to ellipticine.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x chemie $x farmakologie $7 D000970
650    _2
$a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
650    _2
$a adukty DNA $x účinky léků $7 D018736
650    _2
$a elipticiny $x chemie $x farmakologie $7 D004611
650    _2
$a lidé $7 D006801
650    _2
$a oxidace-redukce $7 D010084
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Rupertová, Martina. $7 _AN043711 $u Department of Biochemistry, Faculty of Science, Charles University, Prague 2
700    1_
$a Schmeiser, Heinz H. $u Division of Molecular Toxicology, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg
700    1_
$a Frei, Eva. $7 _AN036392 $u Division of Molecular Toxicology, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic $x 1213-8118 $g Roč. 150, č. 1 (2006), s. 13-23
910    __
$a ABA008 $b A 1502 $c sign $y 3 $z 0
990    __
$a 20130128 $b ABA008
991    __
$a 20130315141758 $b ABA008
999    __
$a ok $b bmc $g 966360 $s 801899
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2006 $b 150 $c 1 $d 13-23 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK111 $a Pubmed-20130128

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...